<unk>  is indicated to be used with diet and exercise to lower blood sugar in adults with type 2 diabetes; to reduce the risk of major heart-related events such as heart attack, stroke, or death in people with type 2 diabetes who have known heart disease; and to reduce the risk of end-stage kidney disease, worsening of kidney function, heart-related death, and being hospitalized for heart failure in certain people with type 2 diabetes and diabetic kidney disease.<unk>  is an anti-diabetic medication used to improve blood sugar control in people with type 2 diabetes. It is a third-line medication to metformin. Per the British National Formulary it is also less preferred than a sulfonylurea as of 2019, while the American Diabetes Association and European Association for the Study of Diabetes consider either a SGLT2 inhibitor or GLP-1 receptor agonist a reasonable second line medication in those with heart disease.<unk>  decreases HbA1c levels by 0.77% to 1.16% when given by itself, in combination with metformin, in combination with metformin and a sulfonylurea, in combination with metformin and pioglitazone, or in combination with insulin, from initial HbA1c levels of 7.8% to 8.1%. When added to metformin,<unk>  does not appear worse than sitagliptin or glimepiride in reducing HbA1c levels, while<unk>  maybe better than sitagliptin and glimiperide in decreasing HbA1c. It is unclear whether or not it has any unique cardiovascular benefits beyond lowering blood sugar. Although<unk>  produces beneficial effects on HDL cholesterol, it has also been shown to increase LDL cholesterol to produce no change in total cholesterol. Evidence shows that apart from positive effects on glycemic levels,<unk>  also reduces the risk of heart attacks and heart failures. SGLT2 inhibitors, including<unk> , reduce the likelihood of hospitalization for congestive heart failure or progression of renal disease in persons with diabetes mellitus type 2 and reduce the likelihood of stroke and heart attack in persons with diabetes mellitus type 2 who have known atherosclerotic vascular disease.
Canagliflozin
Linagliptin
Empagliflozin
Dapagliflozin
Liraglutide
Sotagliflozin
Exenatide
Vildagliptin